公开(公告)号：US20240009265A1

公开(公告)日：2024-01-11

申请号：US17922487

申请日：2021-04-30

申请人： Blue Sky Innovation, LLC

发明人： Danny C. Purser ,  Stephen N. Pitcher

IPC分类号： A61K38/06 ,  A61K9/00 ,  A61P17/02 ,  A61K31/545 ,  A61K9/127

CPC分类号： A61K38/063 ,  A61K9/0014 ,  A61P17/02 ,  A61K31/545 ,  A61K9/127

摘要： The present disclosure is drawn to a method of treating a subject having a condition responsive to treatment with reduced glutathione (rGSH), comprising: administering a therapeutically effective amount of a substantially α-D-glucopyranoside-free stabilized rGSH composition to the subject.

公开(公告)号：US20230398194A1

公开(公告)日：2023-12-14

申请号：US18323578

申请日：2023-05-25

申请人： Theriva Biologics, Inc.

发明人： Sheila CONNELLY ,  Michael KALEKO

IPC分类号： A61K38/50 ,  A61K31/407 ,  A61K31/43 ,  A61K31/546 ,  A61K38/14 ,  C12Q1/6876 ,  A61K31/545 ,  A61K35/74 ,  C12N9/86 ,  A61P1/00

CPC分类号： A61K38/50 ,  A61K31/407 ,  A61K31/43 ,  A61K31/546 ,  A61K38/14 ,  C12Q1/6876 ,  C12Y305/02006 ,  A61K31/545 ,  A61K35/74 ,  C12N9/86 ,  A61P1/00 ,  C12Q2600/106 ,  C12Q2600/158

摘要： The present invention provides, in part, therapeutic beta-lactamases that can, inter alia, mitigate antibiotic resistance.

公开(公告)号：US20230331724A1

公开(公告)日：2023-10-19

申请号：US18199019

申请日：2023-05-18

申请人： MEIJI SEIKA PHARMA CO., LTD.

发明人： Takao ABE ,  Takeshi FURUUCHI ,  Yoshiaki SAKAMAKI ,  Seiichi INAMURA ,  Akihiro MORINAKA

IPC分类号： C07D471/08 ,  A61K31/439 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/407 ,  A61K31/4162 ,  A61K31/427 ,  A61K45/06 ,  A61K31/43 ,  A61K31/545 ,  A61K31/546 ,  C07D211/60 ,  A61K31/444 ,  A61K31/437 ,  C07F7/08

CPC分类号： C07D471/08 ,  A61K31/439 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/407 ,  A61K31/4162 ,  A61K31/427 ,  A61K45/06 ,  A61K31/43 ,  A61K31/545 ,  A61K31/546 ,  C07D211/60 ,  A61K31/444 ,  A61K31/437 ,  C07F7/0812 ,  Y02P20/55

摘要： A process for preparing a diazabicyclooctane compound represented by the following formula (I):




wherein A represents RcO—; B represents NH or NC1-6 alkyl; C represents a benzyl group; Rc represents a C1-6 alkyl group; A is substituted with one substituent Fn1, wherein Fn1 represents an azetidine group; the process including: (a) silylating the compound represented by the following formula (IV-c):




wherein in the formula (IV-c), OBn represents benzyloxy, and (b) carrying out an intramolecular urea formation reaction.

公开(公告)号：US11731971B2

公开(公告)日：2023-08-22

申请号：US17399618

申请日：2021-08-11

申请人： MEIJI SEIKA PHARMA CO., LTD.

发明人： Takao Abe ,  Takeshi Furuuchi ,  Yoshiaki Sakamaki

IPC分类号： C07D471/08 ,  A61K31/439 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/407 ,  A61K31/4162 ,  A61K31/427 ,  A61K45/06 ,  A61K31/43 ,  A61K31/545 ,  A61K31/546 ,  C07D211/60 ,  A61K31/444 ,  A61K31/437 ,  C07F7/08

CPC分类号： C07D471/08 ,  A61K31/407 ,  A61K31/4162 ,  A61K31/427 ,  A61K31/43 ,  A61K31/437 ,  A61K31/439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/545 ,  A61K31/546 ,  A61K45/06 ,  C07D211/60 ,  C07F7/0812 ,  Y02P20/55 ,  A61K31/43 ,  A61K2300/00 ,  A61K31/545 ,  A61K2300/00 ,  A61K31/546 ,  A61K2300/00 ,  A61K31/407 ,  A61K2300/00 ,  A61K31/4162 ,  A61K2300/00 ,  A61K31/427 ,  A61K2300/00 ,  A61K31/439 ,  A61K2300/00 ,  A61K31/4545 ,  A61K2300/00 ,  A61K31/5377 ,  A61K2300/00

摘要： A process for preparing a diazabicyclooctane compound represented by the following formula (I):




wherein A represents RcO—; B represents NH or NC1-6 alkyl; C represents a benzyl group; Rc represents a C1-6 alkyl group; A is substituted with one substituent Fn1, wherein Fn1 represents an azetidine group; the process including: (a) silylating the compound represented by the following formula (IV-c):





wherein in the formula (IV-c), OBn represents benzyloxy, and (b) carrying out an intramolecular urea formation reaction.

公开(公告)号：US20230233575A1

公开(公告)日：2023-07-27

申请号：US18001867

申请日：2021-01-26

申请人： CHINA PETROLEUM & CHEMICAL CORPORATION ,  SINOPEC RESEARCH INSTITURE OF SAFETY ENGINEERING CO., LTD.

发明人： Kele YAN ,  Anshan XIAO ,  Shanjun MU ,  Xuyao HU ,  Yuemeng REN ,  Hongxing ZHANG ,  Yu LIN

IPC分类号： A61K31/545 ,  A61K31/43 ,  A61K9/46 ,  A61K47/18 ,  A61K31/40 ,  A61K47/26 ,  A61K47/36 ,  A61K47/02

CPC分类号： A61K31/545 ,  A61K31/43 ,  A61K9/0007 ,  A61K47/186 ,  A61K31/40 ,  A61K47/26 ,  A61K47/36 ,  A61K47/02

摘要： A hydrate promoter contains a component A which is a substance having a group represented by the Formula I below and a surfactant. A molar ratio of the component A to the surfactant is 1:(0.03-30). The hydrate overcomes the disadvantages of the conventional hydrate promoter, such as small gas storage capacity and low generation rate, the present disclosure is further capable of suppressing generation of air bubbles and improving the gas recovery rate of hydrate during decomposition process of the hydrate, as compared to the conventional hydrate promoter, thus has a favorable application prospect for natural gas storage and transportation with the hydrate.

公开(公告)号：US11696939B2

公开(公告)日：2023-07-11

申请号：US17138864

申请日：2020-12-30

申请人： ILIAS Biologics Inc ,  ILIAS Therapeutics, Inc.

发明人： Chulhee Choi ,  Kyungsun Choi ,  Ramkumar Menon

IPC分类号： A61K35/12 ,  A61K38/17 ,  A61K47/69 ,  A61P15/06 ,  A61K38/095 ,  A61K9/127 ,  A61K31/137 ,  A61K31/4025 ,  A61K31/405 ,  A61K31/43 ,  A61K31/4422 ,  A61K31/545 ,  A61K31/57 ,  A61K31/7048 ,  A61K33/06 ,  A61K38/16 ,  A61K38/45 ,  A61K38/51

CPC分类号： A61K38/1738 ,  A61K9/127 ,  A61K31/137 ,  A61K31/405 ,  A61K31/4025 ,  A61K31/43 ,  A61K31/4422 ,  A61K31/545 ,  A61K31/57 ,  A61K31/7048 ,  A61K33/06 ,  A61K38/095 ,  A61K38/164 ,  A61K38/168 ,  A61K38/1709 ,  A61K38/1774 ,  A61K38/45 ,  A61K38/51 ,  A61K47/6911 ,  A61P15/06

摘要： The present invention is related to compositions containing extracellular vesicles (exosomes) and methods of using the same for increasing lifespan of fetus, viability of fetus, or viability of newborn, for treating inflammation in uterus and/or fetus, for delaying preterm birth, or for treating a condition related to inflammation in uterus and/or fetus, wherein the extracellular vesicles comprising a nuclear factor kappa beta (NF-κB) inhibitor and a photo-specific binding protein.

公开(公告)号：US20230096220A1

公开(公告)日：2023-03-30

申请号：US17800261

申请日：2021-02-26

申请人： Zydus Lifesciences Limited

发明人： Rajiv SHARMA ,  Sameer AGARWAL

IPC分类号： A61K31/64 ,  C07C311/55 ,  C07D309/14 ,  C07D211/58 ,  C07D335/02 ,  C07D295/084 ,  C07D295/13 ,  C07C381/10 ,  A61K38/21 ,  A61K38/20 ,  A61K31/545 ,  A61K45/06

摘要： The present invention relates to novel compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds and their use as the compounds of the invention belong to the family of NOD-like receptor family (NLR) protein NLRP3 modulators. The present invention thus relates to novel NLRP3 modulators as well as to the use of the novel inhibitor compounds in the treatment of diseases or conditions in which interleukin 1β activity is implicated.

公开(公告)号：US20220257710A1

公开(公告)日：2022-08-18

申请号：US17627805

申请日：2019-07-17

申请人： INSTITUTE OF BASIC MEDICAL SCIENCES, CHINESE ACADEMY OF MEDICAL SCIENCES

发明人： Xuetao CAO ,  Lei WANG ,  Mingyue WEN

IPC分类号： A61K38/17 ,  A61K31/43 ,  A61K31/65 ,  A61K31/675 ,  A61K31/4706 ,  A61K38/13 ,  A61K39/395 ,  A61K38/21 ,  A61K31/545 ,  A61K31/165 ,  A61K36/37 ,  A61K49/00 ,  A61P31/22 ,  C12N15/113

摘要： Provided are anti-infection effects of a heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) and use thereof. In particular, provided are use of hnRNPA2B1, a nucleic acid molecule encoding the protein, and an accelerator thereof or an inhibitor thereof in the preparation of a product for preventing and/or treating infectious diseases and/or diseases and/or conditions associated with infection, and a corresponding pharmaceutical composition or kit thereof. The present disclosure can be used for preventing and inhibiting infections (such as virus infections) and diagnosing and treating autoimmune diseases related to self-nucleic acids, and has wide application prospects.

公开(公告)号：US20220194964A1

公开(公告)日：2022-06-23

申请号：US17599913

申请日：2020-04-01

申请人： Venatorx Pharmaceuticals, Inc.

发明人： Christopher J. BURNS ,  Lawrence ROSEN ,  Stephen M. CONDON ,  Eugen F. MESAROS ,  Allison L. ZULLI ,  Robert E. Lee TROUT ,  Yijun DENG ,  Steven A. BOYD ,  Robert SIMPSON

IPC分类号： C07F5/02 ,  A61K31/545 ,  A61K45/06

摘要： Disclosed herein are crystalline forms of ((2-Ethylbutanoyl)oxy)methyl (R)-2-hydroxy-3-propionamido-3,4-dihydro-2H-benzo[e][1,2]oxaborinine-8-carboxylate. Also disclosed herein are methods of treating a bacterial with a crystalline form of ((2-Ethylbutanoyl)oxy)methyl (R)-2-hydroxy-3-propionamido-3,4-dihydro-2H-benzo[e][1,2]oxaborinine-8-carboxylate.

公开(公告)号：US11324730B2

公开(公告)日：2022-05-10

申请号：US16925811

申请日：2020-07-10

申请人： Alpha-1 Biologics, LLC

发明人： Cynthia L. Bristow ,  Ronald Winston

IPC分类号： A61K31/43 ,  A61K39/395 ,  A61K31/407 ,  A61K31/431 ,  A61K31/545 ,  A61K31/546 ,  A61P11/00 ,  A61P35/00 ,  A61K45/06

摘要： A method for increasing the number of CD4+ T-lymphocytes in the serum of a subject in need of such treatment comprising administering to the subject a pharmaceutical composition comprising an amount of an L-isomer of β-lactam effective to increase the number of CD4+ T-lymphocytes in said patient's serum.